ferret
model
sever
acut
respiratori
syndrom
sar
cov
infect
use
evalu
efficaci
adenoviru
vaccin
anim
subject
heterolog
primeboost
use
vector
human
serotyp
chimpanze
deriv
adenovirus
human
chimpanze
express
spike
protein
follow
intranas
challeng
sarscov
vaccin
led
substanti
reduct
viral
load
prevent
sever
pneumonia
seen
unvaccin
anim
primeboost
strategi
effect
rhesu
macaqu
elicit
sarscov
specif
immun
respons
data
indic
heterolog
adenovirusbas
primeboost
vaccin
strategi
could
safe
stimul
strong
immun
may
need
complet
protect
sarscov
infect
sever
acut
respiratori
syndrom
sar
caus
new
coronaviru
call
sarscov
phylogenet
distinct
known
human
anim
coronavirus
viru
emerg
highli
aggress
pathogen
adult
age
human
popul
result
animaltohuman
transmiss
follow
high
rate
humantohuman
transmiss
recent
data
suggest
bat
may
anim
reservoir
sarscov
sarscov
replic
cytoplasm
host
cell
contain
singlestrand
plussens
rna
genom
kb
length
major
viral
protein
includ
spike
membran
nucleocapsid
n
protein
main
clinic
symptom
sarscov
infect
sever
respiratori
ill
although
sarscov
also
caus
infect
organ
gastrointestin
urinari
tract
infect
individu
die
within
day
onset
symptom
show
diffus
alveolar
damag
mix
alveolar
infiltr
lung
edema
hyalin
membran
format
sever
inflammatori
cytokin
chemokin
found
elev
infect
individu
whether
sar
reemerg
remain
open
question
uncertainti
precis
step
involv
initi
zoonot
transmiss
new
data
regard
high
preval
bat
popul
rais
concern
human
infect
sarscov
return
hit
run
behavior
well
known
phenomenon
sever
highli
pathogen
agent
ebola
marburg
hemorrhag
fever
virus
also
appear
resid
bat
popul
therefor
prudent
approach
would
support
develop
prevent
cur
strategi
protect
sarscov
reemerg
critic
evalu
vaccin
efficaci
hamper
limit
authent
anim
model
intrapulmonari
administr
sarscov
immun
compet
rodent
result
infect
replic
although
viru
rapidli
clear
littl
patholog
mild
bronchiol
outcom
substanti
differ
anim
defect
host
respons
defici
anim
develop
progress
infect
sever
lung
patholog
wide
dissemin
viru
initi
studi
sarscov
infect
cynomolgu
macaqu
indic
anim
develop
clinic
syndrom
lung
histopatholog
similar
observ
sar
subsequ
sarscov
infect
studi
cynomolgu
rhesu
macaqu
african
green
monkey
two
differ
group
fail
demonstr
signific
clinic
sequela
limit
replic
viru
initi
report
ferret
expos
sarscov
describ
animaltoanim
transmiss
develop
lethal
syndrom
associ
lung
patholog
subsequ
work
group
ferret
model
show
replic
sarscov
lung
pneumonia
vaccin
strategi
attempt
elicit
neutral
antibodi
nab
cell
sarscov
antigen
kill
sarscov
pseudo
particl
protein
subunit
vaccin
contain
produc
nab
sarscov
mous
model
inhibit
viru
replic
vitro
fact
clinic
trial
inactiv
sarscov
underway
china
http
wwwsfdagovcn
searchword
dfand
http
www
searchword
dfand
varieti
genet
vaccin
express
variou
sarscov
open
read
frame
n
also
test
mice
shown
product
sarscov
nab
cell
protect
term
diminish
viru
replic
vivo
human
adenoviru
vector
express
sarscov
antigen
shown
immunogen
macaqu
previou
studi
evalu
number
adenoviru
construct
immunogen
mice
experi
identifi
two
adenoviru
vector
capabl
elicit
high
cell
respons
protein
sarscov
follow
intramuscular
inject
two
differ
strain
mice
first
vector
express
codon
optim
open
read
frame
ie
ns
cmv
promot
delet
genom
human
serotyp
adenoviru
second
vector
express
open
read
frame
optim
chicken
promotercmv
enhanc
delet
genom
chimpanze
adenoviru
two
vector
serolog
distinct
one
anoth
addit
advantag
chimpanze
vector
preexist
immun
human
natur
adenoviru
infect
diminish
efficaci
studi
util
vaccin
platform
base
adenovirus
isol
chimpanze
develop
evalu
vaccin
sarscov
use
ferret
model
complementari
dna
cdna
gene
isol
rtpcr
viral
rna
sarscov
isol
pcr
fragment
clone
topo
invitrogen
ca
character
sequenc
seqwright
seqwright
tx
found
ident
publish
sequenc
codon
optim
cdna
clone
gene
use
templat
amplifi
overlap
oligonucleotid
human
codon
usag
introduc
result
overlap
pcr
fragment
fuse
fulllength
codon
optim
cdna
ns
creat
plasmid
molecular
clone
vector
creat
direct
clone
ns
insert
greenwhit
select
procedur
describ
elsewher
chicken
hybrid
promot
use
drive
express
ns
creat
delet
bp
apa
iafl
ii
fragment
origin
cagg
promot
product
replicationdefect
viral
vector
respect
dna
transfect
cell
viru
rescu
rescu
vector
expand
largescal
infect
cell
purifi
standard
cscl
gradient
sediment
method
cscl
remov
desalt
use
biogel
equilibr
phosphat
buffer
salin
pb
viru
prepar
suspend
pb
glycerol
kept
c
genom
structur
vector
confirm
restrict
analysi
age
plu
bsrgi
age
plu
afliii
visual
inspect
agaros
gel
stain
ethidium
bromid
infect
viral
vector
determin
standard
plaqu
assay
cell
level
replic
compet
adenoviru
rca
contamin
vector
prepar
inspect
describ
previous
viral
vector
prepar
character
concentr
physic
particl
measur
viral
dna
particl
concentr
spectrophotometer
nm
concentr
infecti
viru
rca
genom
integr
enzymat
restrict
see
absenc
endotoxin
use
limulu
amebocyt
lysat
lal
gelclot
method
bio
whittak
md
qualiti
control
assay
confirm
presenc
highli
infecti
intact
recombin
viral
vector
case
except
prepar
use
nonhuman
primat
nhp
studi
learn
subsequ
inject
delet
gene
genom
dose
indic
prepar
reflect
number
intact
viral
vector
four
adult
chines
rhesu
macaqu
free
neutral
antibodi
purchas
covanc
research
product
alic
texa
primat
hous
nonhuman
primat
facil
divis
medic
genet
univers
pennsylvania
rhesu
macaqu
immun
intramuscular
im
inject
quadricep
femori
vastu
laterali
muscl
anim
prime
viral
particl
intact
subsequ
boost
week
particl
viral
particl
dilut
steril
normal
salin
total
volum
ml
vector
deliv
two
inject
site
leg
per
anim
red
top
serum
separ
tube
use
collect
venou
blood
order
isol
serum
pbmc
isol
whole
blood
collect
ethylenediaminetetraacet
acid
edta
contain
vacutain
tube
ficol
densiti
gradient
centrifug
g
min
cell
collect
interphas
wash
phosphat
buffer
salin
resuspend
complet
rpmi
medium
male
fitch
ferret
mustela
putoriu
furo
marshal
farm
north
rose
ny
week
old
weigh
around
kg
held
minimum
day
prior
vaccin
biosafeti
level
laboratori
anim
hold
area
ferret
vaccin
intramuscularli
particleskg
appropri
adenovir
vector
express
sarscov
protein
one
group
six
ferret
boost
intramuscularli
day
postprim
particleskg
blood
sampl
taken
week
andor
test
presenc
nab
sarscov
prolifer
lymphocyt
respons
restimul
sarscov
see
detail
ferret
sent
southern
research
institut
held
laboratori
prior
challeng
quarantin
period
baselin
temperatur
measur
use
subcutan
implant
temperatur
transpond
biomed
data
system
inc
seaford
de
preinfect
valu
averag
obtain
baselin
temperatur
ferret
follow
challeng
temperatur
measur
daili
approxim
time
day
chang
temperatur
degre
fahrenheit
calcul
time
point
anim
clinic
sign
sneez
anesthesia
inappet
dyspnea
level
activ
assess
daili
time
challeng
ferret
first
anesthet
ketamin
mgkg
xylazin
mgkg
atropin
mgkg
follow
intranas
challeng
total
pfu
sarscov
strain
see
propag
assay
sarscov
ml
phosphat
buffer
salin
deliv
nostril
anim
hous
aaalacaccredit
facil
procedur
accord
nrc
guid
care
use
laboratori
anim
anim
welfar
act
biosafeti
microbiolog
biomed
laboratori
addit
procedur
approv
southern
research
institut
institut
anim
care
use
committe
southern
research
institut
institut
biosafeti
committe
sampl
collect
process
accord
standard
procedur
nasal
wash
collect
day
ferret
sedat
ketamin
mgkg
ml
steril
pb
contain
bovin
serum
albumin
penicillin
uml
streptomycin
gml
gentamicin
gml
inject
nostril
collect
petri
dish
expel
ferret
sedat
ferret
weigh
bled
via
venipunctur
anterior
vena
cava
prior
infect
time
sacrific
ml
blood
collect
heparin
tube
ferret
euthan
postchalleng
intracardiac
inject
beuthanasiad
solut
euthanasia
solut
kg
bodi
weight
scheringplough
anim
health
corp
nj
gross
necropsi
abdomen
thorax
perform
lung
collect
either
frozen
dri
ice
viru
isol
place
formalin
histolog
analys
tissu
sampl
nasal
wash
immedi
place
dri
ice
subsequ
store
c
viral
load
determin
histolog
tissu
remov
necropsi
cut
small
piec
fix
neutral
buffer
formalin
day
lung
inflat
formalin
cut
piec
immers
formalin
day
tissu
extens
rins
tap
water
remov
formalin
store
ethanol
tissu
later
embed
paraffin
section
prepar
glass
slide
stain
hematoxylin
eosin
analyz
light
microscopi
detect
sarscov
antigen
immunohistochemistri
perform
formalinfix
paraffinembed
tissu
rabbit
antibodi
direct
nterminu
nucleocapsid
n
protein
dilut
abgent
san
diego
ca
briefli
section
deparaffin
three
wash
xylen
min
follow
descend
ethanol
seri
twice
ethanol
water
boil
microwav
min
mm
citrat
buffer
ph
treat
sequenti
h
avidinbiotin
block
reagent
vector
laboratori
burlingam
ca
protein
block
agent
fisher
scientif
follow
incub
primari
biotinyl
secondari
antibodi
vector
vectastain
elit
abc
kit
vector
use
dab
substrat
visual
bound
antibodi
brown
precipit
section
slightli
counterstain
hematoxylin
show
nuclei
sarscov
strain
kindli
provid
dr
heinz
feldmann
canadian
scienc
centr
human
anim
health
winnipeg
canada
health
canada
viru
isol
fatal
canadian
sar
case
passag
twice
cell
health
canada
viru
passag
cell
gener
viru
stock
titer
pfuml
standard
plaqu
assay
briefli
confluent
monolay
cell
infect
cm
tissu
cultur
flask
costar
contain
ml
dmem
viru
moi
flask
incub
c
co
h
rock
everi
min
h
ml
dmem
supplement
uml
penicillin
gml
streptomycin
mm
lglutamin
bovin
serum
albumin
bsa
ad
flask
flask
incub
monitor
daili
appear
virusspecif
cytopath
effect
cpe
cpe
observ
cell
harvest
scrape
remov
adher
cell
cell
suspens
centrifug
g
min
c
pellet
cell
clarifi
cultur
fluid
contain
viru
aliquot
ml
volum
store
c
use
frozen
lung
sampl
homogen
ml
pb
contain
penicillin
uml
streptomycin
gml
gentamicin
gml
homogen
clarifi
centrifug
g
min
c
result
supernat
bronchoalveolar
lavag
bal
nasal
wash
nw
sampl
serial
dilut
fivefold
etc
dmem
contain
heatinactiv
fetal
bovin
serum
atlanta
biolog
atlanta
ga
antibiot
penicillin
streptomycin
predilut
process
sampl
ad
confluent
cell
remov
cultur
medium
well
per
sampl
l
per
well
plate
monitor
cytopat
effect
cpe
cell
use
differ
assay
differ
note
sarscov
suscept
replic
kinet
approxim
h
incub
maximum
cpe
posit
control
c
co
cpe
measur
neutral
red
stain
well
follow
measur
absorb
nm
titr
report
reciproc
dilut
requir
infect
cell
cultur
per
millilit
valu
calcul
accord
method
reed
muench
number
sarscov
genom
ferret
tissu
sampl
quantifi
use
rt
taqman
assay
fifti
mg
tissu
homogen
ml
trizol
use
dispos
tissu
grinder
kendal
sampl
volum
exceed
trizol
reagent
use
homogen
trizol
reagent
ad
expediti
possibl
minim
rna
degrad
homogen
snapfrozen
store
c
time
process
sampl
allow
thaw
ice
rna
extract
perform
accord
manufactur
instruct
total
rna
sampl
quantifi
spectrophotomet
rna
integr
inspect
agaros
gel
compar
transcript
hous
keep
gene
gapdh
real
time
rtpcr
one
microgram
total
tissu
rna
reversetranscrib
use
highcapac
cdna
archiv
kit
appli
biosystem
ca
follow
manufactur
instruct
crude
sarscov
rna
extract
infect
cell
describ
tissu
sampl
serv
control
rtpcr
run
real
time
pcr
reaction
primer
probe
set
design
target
n
gene
sarscov
restrict
fragment
n
gene
isol
plasmid
serial
dilut
use
templat
establish
standard
curv
onetenth
rt
reaction
use
per
taqman
pcr
reaction
carri
abi
prism
tm
sequenc
detector
appli
biosystem
manufactur
suggest
condit
result
express
genom
copi
number
per
microgram
g
total
rna
extract
repres
tissu
sampl
ie
ferret
lung
etc
sera
collect
immun
ferret
inactiv
c
min
serial
dilut
sampl
etc
l
dmem
mix
equal
volum
sarscov
pfuwel
incub
c
min
mixtur
transfer
onto
subconflu
cell
flatbottom
plate
incub
min
c
co
control
well
infect
equal
amount
viru
without
addit
serum
nonimmun
serum
one
hundr
microlit
dmem
supplement
fb
ad
well
plate
incub
c
co
day
cell
subsequ
score
presenc
cpe
light
microscop
lowest
sampl
dilut
cpe
could
detect
taken
nab
titer
eg
lymphoprolifer
assay
ferret
pbmc
harvest
ml
whole
blood
edtablood
vacutain
tube
isol
follow
ficollhypaqu
densiti
gradient
centrifug
g
min
wash
pb
resuspend
rpmi
supplement
fc
antibiot
final
concentr
penicillin
vv
streptomycin
vv
gentamycin
wv
triplic
cultur
l
pbmcsml
cultur
heat
inactiv
sarscov
pfuml
equival
medium
alon
heat
inactiv
perform
incub
viru
c
h
h
incub
tritiat
thymidin
amersham
bioscienc
nj
ad
well
uciwel
prolifer
measur
hthymidin
puls
wallach
liquid
scintil
counter
gaithersburg
md
usa
result
present
stimul
indic
si
denot
ratio
activ
cpm
stimul
cultur
activ
cpm
unstimul
cultur
elispot
perform
describ
previous
modif
primari
coat
antibodi
use
antihuman
clone
mabtech
inc
oh
concentr
gml
briefli
elispot
plate
coat
captur
antibodi
clone
mabtech
inc
overnight
c
pbmc
plate
appropri
stimuli
duplic
two
cell
densiti
cell
per
well
antigen
specif
stimul
cell
stimul
sarss
specif
peptid
librari
mer
aa
overlap
total
pool
peptidespool
mimotop
pti
ltd
australia
cell
also
stimul
staphylococc
enterotoxin
b
sigmaaldrich
medium
alon
posit
neg
control
respect
incub
h
plate
wash
subsequ
treat
detect
antibodi
biotinyl
antihuman
polyclon
antibodi
follow
appropri
secondari
color
develop
agent
conjug
streptavidinhrp
reveal
aec
chromogen
substrat
solut
bd
bioscienc
ca
spot
enumer
eye
use
stereo
dissect
microscop
express
number
spot
form
cell
sfc
million
pbmc
unit
intracellular
cytokin
stain
assay
perform
follow
briefli
pbmc
stimul
five
sar
peptid
pool
final
concentr
gml
peptid
hour
co
complet
medium
contain
costimulatori
antibodi
pharmingen
brefeldina
pharmingen
ad
stimul
medium
addit
h
c
forc
intracellular
accumul
follow
stimul
cell
subsequ
fix
permeabil
cytofixcytoperm
pharmingen
min
ice
stain
antibodi
label
fluoresc
dye
apc
stain
cell
run
dakocytom
cyan
lx
flow
cytomet
acquir
least
event
per
sampl
final
data
analys
perform
use
softwar
flowjo
respons
consid
posit
frequenc
stimul
sampl
threefold
higher
nonstimul
stimul
unrel
peptid
control
sampl
data
analyz
statist
differ
perform
unpair
ttest
twotail
pvalu
method
kolmogorov
smirnov
oneway
analysi
varianc
anova
tukeykram
multipl
comparison
test
multipl
comparison
versu
control
group
holmsidak
method
appropri
differ
mean
raw
valu
among
treatment
group
consid
signific
p
experi
involv
manipul
replicationcompet
sarscov
perform
biosafeti
level
contain
approv
southern
research
institut
institut
biosafeti
committe
univers
pennsylvania
institut
biosafeti
committe
ferret
use
model
studi
human
pulmonari
biolog
anatom
function
similar
human
lung
number
human
respiratori
pathogen
influenza
effect
model
ferret
use
evalu
efficaci
therapeut
vaccin
order
develop
model
sar
use
evalu
efficaci
adenoviru
vaccin
infect
ferret
sarscov
strain
via
intranas
administr
follow
infect
anim
monitor
clinic
sign
diseas
evid
viral
replic
patholog
pilot
studi
anim
follow
month
infect
demonstr
develop
sever
respiratori
ill
highest
level
circul
viru
day
peak
patholog
occur
day
infect
anim
surviv
sarscov
infect
long
recoveri
period
although
diseas
lethal
rare
occas
manuscript
prepar
base
studi
group
three
ferret
immun
intramuscularli
genomeskg
control
adenovirusbas
vaccin
evalu
vaccin
efficaci
day
challeng
specif
studi
includ
daili
observ
sign
ill
harvest
rectal
swab
nasal
wash
analysi
infecti
viru
viral
genom
day
necropsi
anim
day
analysi
tissu
viral
load
patholog
express
sarscov
antigen
mean
activ
score
repres
group
averag
daili
activ
score
ferret
score
normal
alert
play
stimul
alert
play
stimul
neither
alert
play
stimul
score
system
base
describ
reuman
et
al
b
percent
ferret
per
group
serou
nasal
discharg
note
nasal
discharg
mainli
resolv
day
six
ferret
per
group
evalu
day
ferret
per
group
day
control
group
describ
repres
anim
vaccin
human
adenoviru
vector
express
lacz
gene
ident
find
obtain
ferret
data
shown
soon
infect
sarscov
anim
demonstr
number
clinic
sign
includ
decreas
activ
day
nasal
discharg
day
tabl
basal
bodi
temperatur
record
implant
transpond
increas
f
peak
day
slowli
return
normal
fig
substanti
quantiti
infecti
sarscov
measur
tcid
viral
genom
measur
real
time
pcr
shed
nasal
wash
increas
peak
respect
day
return
lower
still
detect
level
day
fig
group
viral
genom
detect
rectal
swab
day
fig
although
infecti
viru
found
organ
harvest
necropsi
evalu
viral
genom
also
analyz
infecti
viru
signific
find
lung
genom
infecti
viru
measur
high
level
day
fig
group
sarscov
detect
liver
spleen
data
shown
gross
inspect
lung
reveal
larg
patch
red
discolor
surfac
day
data
shown
fig
larg
arrow
addit
well
demarc
smaller
red
punctat
lesion
observ
lung
harvest
day
fig
small
arrow
histolog
analysi
reveal
sever
region
acut
bronchopneumonia
substanti
consolid
contain
mononuclear
cell
neutrophil
fig
panel
g
immunohistochem
studi
demonstr
express
sarscov
n
protein
mononuclear
cell
within
area
consolid
two
six
anim
studi
present
quit
abund
although
mani
area
consolid
detect
fig
anim
posit
high
level
sarscov
genom
infecti
viru
suggest
antibodi
recognit
sarscov
n
antigen
histolog
assay
suboptim
ferret
inject
intramuscularli
genomeskg
group
vector
group
vector
group
combin
prime
boost
group
sera
harvest
day
last
administ
vaccin
analyz
nab
sarscov
fig
fig
antigen
specif
immun
respons
ferret
challeng
sarscov
sera
peripher
blood
mononuclear
cell
collect
day
last
administ
vaccin
analyz
nab
sarscov
lymphoprolifer
lpr
neutral
antibodi
nab
titer
sarscov
sera
vaccin
ferret
nab
titer
express
reciproc
highest
dilut
serum
sarscovmedi
cytopath
effect
observ
vero
cell
sampl
test
triplic
experi
perform
twice
bar
repres
individu
anim
peripher
blood
mononuclear
cell
evalu
cell
respons
use
lpr
assay
heat
inactiv
sarscov
antigen
stimul
b
two
posit
antigenspecif
stimul
control
sampl
consist
pbmc
two
rhesu
macaqu
nhp
receiv
heterolog
primeboost
includ
everi
lpr
assay
lpr
measur
hthymidin
incorpor
present
stimul
index
cpm
sarscov
stimul
cultur
per
cpm
presenc
medium
alon
pbmc
test
triplic
singl
experi
error
bar
repres
standard
deviat
data
log
scale
stimul
index
plot
along
yaxi
singl
administr
either
vector
result
titer
neutral
antibodi
around
reciproc
dilut
heterolog
boost
increas
product
nab
least
four
six
anim
p
measur
cell
respons
limit
outbr
natur
ferret
model
lack
reagent
antibodi
therefor
lymphoprolifer
follow
stimul
heat
inactiv
sarscov
assess
pbmc
harvest
anim
day
prime
control
vector
variou
vaccin
vector
heterolog
primeboost
immun
cell
incub
heat
inactiv
sarscov
sourc
antigen
subsequ
studi
activ
measur
incorpor
hthymidin
dna
pbmc
two
rhesu
macaqu
receiv
primeboost
regimen
use
group
evalu
posit
control
assay
see
elispot
analys
cell
show
high
level
antigen
specif
express
cell
fig
stimul
index
si
rhesu
pbmc
rang
analysi
pbmc
ferret
yield
si
around
one
control
group
si
greater
one
anim
group
although
signific
animaltoanim
variat
immun
anim
fig
overal
experi
singl
immun
either
vector
encourag
complet
temperatur
curv
group
similar
control
fig
clinic
find
decreas
activ
nasal
discharg
significantli
improv
day
respect
tabl
larg
patch
red
discolor
lung
surfac
day
observ
anim
receiv
either
punctat
lesion
observ
lung
harvest
day
frequenc
size
similar
note
control
group
fig
small
arrow
compar
b
vaccin
affect
decreas
infecti
viru
wherea
diminut
note
vaccin
nasal
wash
day
p
although
amount
viral
genom
chang
fig
lung
infecti
sarscov
viral
genom
averag
level
reduc
log
fig
lung
histopatholog
also
significantli
improv
group
immun
singl
dose
vaccin
bronchopneumonia
character
control
group
absent
group
howev
demonstr
rather
diffus
interstiti
inflamm
fig
area
consolid
within
airspac
fig
bronchiol
fig
respons
anim
receiv
primeboost
challeng
sarscov
complet
clinic
find
decreas
activ
subsid
significantli
faster
group
observ
either
control
singl
immun
anim
day
instead
nasal
discharg
note
one
anim
six
day
tabl
fever
lessen
peak
delay
day
fig
infecti
sarscov
level
nasal
wash
decreas
log
day
p
infecti
viru
viral
genom
averag
level
lung
homogen
diminish
log
time
point
comparison
anim
receiv
vector
fig
c
impress
improv
relat
lung
histopatholog
evid
abnorm
base
gross
observ
lung
fig
histolog
analys
reveal
broad
area
normal
lung
dispers
foci
interstiti
inflamm
peribronchiolar
inflamm
without
broncho
alveolar
consolid
fig
f
combin
immun
protect
well
ferret
also
evalu
four
rhesu
macaqu
macaqu
follow
develop
nab
sarscov
blood
activ
sarscov
specif
express
cell
pbmc
anim
inject
im
particl
week
later
inject
particl
follow
prime
four
anim
gener
level
nab
sarscov
rang
reciproc
dilut
fig
cell
specif
sarscov
express
measur
use
elispot
assay
peptid
span
entir
open
read
frame
mer
amino
acid
overlap
pool
five
independ
mixtur
detect
cell
respons
obtain
monkey
peak
peptid
pool
occur
around
week
frequenc
rang
spotsmillion
cell
fig
elispot
assay
perform
time
point
three
animalsth
data
fourth
anim
similar
less
time
point
record
thu
anim
omit
fig
anim
show
respons
multipl
pool
rel
activ
vari
differ
anim
level
nab
significantli
increas
anim
averag
follow
boost
p
follow
gradual
declin
level
around
heterolog
boost
also
increas
express
cell
frequenc
rel
peak
follow
prime
respons
observ
within
peptid
pool
observ
prime
four
anim
peak
cell
respons
observ
around
week
follow
boost
select
sampl
peripher
blood
mononuclear
cell
harvest
follow
boost
also
evalu
antigen
specif
cell
respons
use
intracellular
cytokin
stain
assay
fraction
antigen
specif
cell
differ
subset
base
cell
surfac
marker
analysi
show
cellular
respons
primarili
cell
direct
multipl
epitop
anim
cell
respons
detect
two
three
five
differ
peptid
pool
summari
relev
data
shown
tabl
exampl
one
assay
shown
fig
b
cell
respons
persist
week
respect
longest
time
point
follow
number
vaccin
strategi
evalu
prevent
infect
sarscov
mani
approach
inde
elicit
antibodi
neutral
sarscov
vitro
activ
cell
sarscov
epitop
whether
would
provid
protect
sarscov
infect
unclear
correl
protect
defin
approach
util
vaccin
strategi
base
recombin
adenovirus
shown
system
activ
cell
broad
rang
sarscov
epitop
activ
b
cell
secret
high
level
nab
two
anim
model
evalu
assess
efficaci
adenovirusbas
vaccin
primari
evalu
perform
ferret
experi
repres
suscept
reliabl
anim
model
sarscov
infect
high
viru
replic
mark
clinic
patholog
sequela
model
limit
absenc
reagent
measur
cell
respons
potenti
differ
biolog
adenoviru
platform
compar
primat
select
immunolog
studi
therefor
perform
rhesu
macaqu
assess
abil
adenoviru
platform
elicit
sarscov
specif
cell
respons
nab
product
although
protect
challeng
adequ
model
rhesu
singl
administr
either
vector
express
ferret
inde
lead
sarscov
nab
reciproc
dilut
activ
cell
base
vitro
prolifer
assay
fig
adenoviru
vector
inject
individu
substanti
diminish
viral
load
lung
nasal
wash
although
effect
lung
patholog
believ
import
end
point
modest
fig
heterolog
adenoviru
primeboost
increas
nab
product
importantli
almost
complet
prevent
lung
patholog
interest
could
differenti
singl
adenoviru
vaccin
administr
versu
primeboost
strategi
base
viral
load
lung
day
vaccin
group
diminish
almost
baselin
level
fig
import
clinic
efficaci
note
group
receiv
primeboost
immun
regiment
suggest
clinic
outcom
mainli
determin
earli
exposur
sarscov
may
independ
viral
load
later
data
suggest
certain
threshold
nab
togeth
possibl
contribut
viru
specif
cell
may
necessari
clinic
meaning
protect
interest
note
heterolog
boost
increas
si
achiev
prime
fig
may
reflect
real
increas
cell
activ
altern
may
problem
captur
peak
level
cell
activ
differ
kinet
prime
boost
also
possibl
level
cell
activ
primeboost
group
high
vitro
stimul
induc
apoptosi
antigen
specif
cell
previou
report
describ
sever
hepat
ferret
challeng
sarscov
vaccin
modifi
vaccinia
viru
ankara
mva
base
recombin
express
anim
present
studi
care
scrutin
similar
patholog
liver
histolog
analysi
statist
differ
vaccin
group
untreat
ferret
data
shown
number
reason
may
explain
absenc
vaccineinduc
liver
toxic
observ
adenoviru
vaccin
vector
one
vaccin
approach
achiev
substanti
control
viru
replic
case
mva
vaccin
possibl
subtherapeut
vaccin
respons
term
sarscov
nab
cell
may
lead
induc
patholog
gener
enhanc
antibodi
without
suffici
level
protect
cell
nab
evalu
adenoviru
primeboost
strategi
rhesu
macaqu
quit
encourag
high
level
nab
gener
peak
reciproc
dilut
rang
boost
declin
appar
averag
state
level
reciproc
dilut
week
later
fig
level
nab
detect
rhesu
boost
similar
exceed
provid
protect
ferret
model
compar
fig
difficult
compar
cell
respons
ferret
rhesu
macaqu
absenc
reagent
ferret
howev
cell
frequenc
observ
nhp
high
seen
vaccin
project
involv
ebola
hiv
remain
rel
stabl
combin
result
protect
ferret
model
immunogen
nhp
model
suggest
vaccin
strategi
hold
promis
protect
human
sar
